The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

Eli Lilly stock has soared on a new growth wave driven by its diabetes and obesity care treatments. While this has made profit-taking in Lilly stock tempting, the company has several catalysts ahead.

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

Back in September, Lilly received FDA approval for its atopic dermatitis medication Ebglyss. Atopic dermatitis is more commonly referred to as eczema. Eczema is generally treated with topical ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...

New results show Eli Lilly’s (LLY) Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results from the ...

Eli Lilly's EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from the Phase IIIb ADapt study.